Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Scientists map genetic codes of dangerous bacteria

Scientists seeking new ways to fight drug-resistant superbugs have mapped the genomes of more than 3,000 bacteria, including samples of a bug taken from Alexander Fleming’s nose and a dysentery-causing strain from a World War One soldier.

Read More »

AbbVie RA drug succeeds in late-stage study

AbbVie Inc.’ experimental drug upadacitinib met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

Read More »

Tricida Reports Positive Pivotal Phase 3 Study Results

Tricida Inc. announced results from its pivotal Phade 3 clinical trial for TRCA-301 in 217 chronic kidney disease patients with metabolic acidosis.

Read More »

Merck’s Keytruda shows promise in treating advanced melanoma

Merck & Co. Inc. said long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.

Read More »

Mixed study results for cancer drug combo

Mixed results were reported from closely watched studies combining Bristol-Myers Squibb’s cancer immunotherapy Opdivo with Nektar Therapeutics’ experimental drug NKTR-214.

Read More »

Keytruda extends lung cancer survival in two trials

Merck & Co.’s immunotherapy Keytruda improved survival as a stand-alone treatment for newly diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer.

Read More »

Many women with early-stage breast cancer can skip chemotherapy: study

Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after tumor removal, U.S. researchers said.

Read More »

Roche drugs show limited benefit in lung, breast cancer trialsd

In a disappointment for Roche Holding, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials.

Read More »

Esketamine Shows Promise in Depression Studies

Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.

Read More »

Madrigal Pharma reports liver drug study success

Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom